Brief: Matinas Biopharma Announces Positive In Vivo Efficacy Results Of Oral LNC Docetaxel Formulation In A Melanoma Model
07/11/2023 12:34
Nov 7 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES POSITIVE IN VIVO EFFICACY
RESULTS OF
ORAL LNC DOCETAXEL FORMULATION IN A MELANOMA MODEL
* MATINAS BIOPHARMA HOLDINGS INC - NO SYSTEMIC TOXICITIES
WERE
NOTED
Source text for Eikon: ID:nGNX1KkX5C
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing